STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and...
5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call
COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance
Collegium Pharmaceutical (NASDAQ:COLL) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops
Collegium Pharmaceutical: Q2 Earnings Snapshot
– Completed Acquisition of AZSTARYS ® , Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Generated Quarterly Net Revenues of $199.9 Million, Up 6% Year-over-Year...
Barchart Research What to Expect from COLL Earnings COLL Generated August 5, 2026 Current Price $35.74 EPS Estimate $$1.48 Consensus Rating Moderate Buy Average Move 4.85% Collegium's Pain Portfolio Faces...
Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect
1 Cash-Producing Stock Worth Investigating and 2 We Ignore
Winners And Losers Of Q1: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Branded Pharmaceuticals Stocks